These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22492419)

  • 21. [Oral bisphosphonates and CTX. New methods for assessing the degree of risk in maxillo-mandibular osteonecrosis].
    Blanc JL; Chossegros C
    Rev Stomatol Chir Maxillofac; 2008 Jun; 109(3):205-6. PubMed ID: 18533207
    [No Abstract]   [Full Text] [Related]  

  • 22. Fracture risk associated with chronic use of bisphosphonates: evidence today.
    Charopoulos I; Orme S; Giannoudis PV
    Expert Opin Drug Saf; 2011 Jan; 10(1):67-76. PubMed ID: 21121870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
    Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
    J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atypical fractures and molecular environment: What do we know?
    Elniel AR; Giannoudis PV
    Injury; 2018 Nov; 49(11):1953-1958. PubMed ID: 30366688
    [No Abstract]   [Full Text] [Related]  

  • 25. What to make of the new warning on bisphosphonates. Officials acknowledge a connection between the most popular bone drugs and rare thigh fractures.
    Harv Womens Health Watch; 2010 Dec; 18(4):6-7. PubMed ID: 21268797
    [No Abstract]   [Full Text] [Related]  

  • 26. [Place of bisphosphonates in the primary andsecondary prophylaxis of osteoporotic fractures: the role of parenteral therapy--proposal to modify the standards of treatment].
    Deszczyński J; Rawo T; Petelewicz T
    Chir Narzadow Ruchu Ortop Pol; 2011; 76(4):225-31. PubMed ID: 22235647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonates and oral health: primer and an update for the practicing surgeon.
    Assael LA
    Oral Maxillofac Surg Clin North Am; 2011 Aug; 23(3):443-53. PubMed ID: 21798442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient.
    Koka S; Clarke BL; Amin S; Gertz M; Ruggiero SL
    Int J Prosthodont; 2007; 20(2):115-22. PubMed ID: 17455429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comment on the American Association of Oral and Maxillofacial Surgeons statement on bisphosphonates.
    Zahrowski JJ
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1440-1. PubMed ID: 17577522
    [No Abstract]   [Full Text] [Related]  

  • 31. Care required when using bisphosphonates in dental surgical practice.
    Goiato MC; dos Santos DM; Rondon BC; Moreno A; Baptista GT; Verri FR; Dekon SF
    J Craniofac Surg; 2010 Nov; 21(6):1966-70. PubMed ID: 21119471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonates: a potential threat to your patients.
    Dreiman BB
    J Indiana Dent Assoc; 2005-2006 Winter; 84(4):4-9. PubMed ID: 16605211
    [No Abstract]   [Full Text] [Related]  

  • 33. PPIs and fracture risk.
    Med Lett Drugs Ther; 2013 Feb; 55(1410):15-6. PubMed ID: 23459458
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
    ; Khosla S; Burr D; Cauley J; Dempster DW; Ebeling PR; Felsenberg D; Gagel RF; Gilsanz V; Guise T; Koka S; McCauley LK; McGowan J; McKee MD; Mohla S; Pendrys DG; Raisz LG; Ruggiero SL; Shafer DM; Shum L; Silverman SL; Van Poznak CH; Watts N; Woo SB; Shane E
    J Oral Maxillofac Surg; 2008 Jun; 66(6):1320-1; author reply 1321-2. PubMed ID: 18486811
    [No Abstract]   [Full Text] [Related]  

  • 36. Atraumatic extraction of a non-vital tooth in a patient receiving long-term oral bisphosphonates.
    Xiong M; Pearson A; Sabino M; Svoboda L; Ehlis E
    Northwest Dent; 2010; 89(4):27-33. PubMed ID: 20860270
    [No Abstract]   [Full Text] [Related]  

  • 37. Subtrochanteric stress fractures in patients on oral bisphosphonate therapy: an emerging problem.
    Murphy CG; O'Flanagan S; Keogh P; Kenny P
    Acta Orthop Belg; 2011 Oct; 77(5):632-7. PubMed ID: 22187839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates and bisphosphonate induced osteonecrosis.
    Sawatari Y; Marx RE
    Oral Maxillofac Surg Clin North Am; 2007 Nov; 19(4):487-98, v-vi. PubMed ID: 18088900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral bisphosphonates and oesophageal cancer.
    Wysowski DK
    BMJ; 2010 Sep; 341():c4506. PubMed ID: 20813821
    [No Abstract]   [Full Text] [Related]  

  • 40. Bone up on proton pump inhibitors and fracture risk.
    Gendreau-Webb R
    Nursing; 2007 Oct; 37(10):60-1. PubMed ID: 17906557
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.